Methods for making Apo-2 ligand using divalent metal ions

Details Methods for making Apo-2 ligand using divalent metal ions Methods for making Apo-2 ligand using divalent metal ions

2006-09-28

2010-12-21

Spector, Lorraine (Department: 1646)

Chemistry: molecular biology and microbiology

Micro-organism, per se ; compositions thereof; proces of...

Bacteria or actinomycetales; media therefor

C530S350000, C435S069100, C435S320100

Reexamination Certificate

active

07855066

ABSTRACT:
Methods of making Apo-2 ligand and formulations of Apo-2 ligand using divalent metal ions are provided. Such divalent metal ions include zinc and cobalt which improve Apo-2 ligand trimer formation and stability. The crystal structure of Apo-2 ligand is also provided, along with Apo-2 ligand variant polypeptides identified using oligonucleotide-directed mutagenesis.

REFERENCES:
patent: 5763223 (1998-06-01), Wiley et al.
patent: 5863760 (1999-01-01), Light et al.
patent: 6387650 (2002-05-01), Townsend et al.
patent: 417563 (1991-03-01), None
patent: WO 92/03478 (1992-03-01), None
patent: WO 92/17200 (1992-10-01), None
patent: WO 97/01633 (1997-01-01), None
patent: WO 97/23615 (1997-07-01), None
patent: WO 97/25428 (1997-07-01), None
patent: WO 97/33899 (1997-09-01), None
patent: WO 97/46686 (1997-12-01), None
patent: WO 98/14577 (1998-04-01), None
patent: 98/51793 (1998-11-01), None
patent: WO 99/10484 (1999-03-01), None
patent: WO 99/36535 (1999-07-01), None
patent: WO 00/02900 (2000-01-01), None
patent: WO 01/18041 (2001-03-01), None
patent: WO 01/18055 (2001-03-01), None
Hymowitz et al., A unique zinc-binding site revealed by a high-resolution X-ray structure of homotrimeric Apo2L/TRAIL, Biochem. 39:633-640, 2000.
Sambrook et al., Molecular Cloning, Cold Spring Harbor Laboratory Press (USA), 2ndEd., pp. A.2-A.3, 1989.
Kim et al., Overexpression of archaeal proteins inEscherichia coli, Biochem. Lett. 20(3):207-210, Mar. 1998.
RPMI-1640 Medium Formulation, Catalogue No. 30-2001, American Type Culture Collection, 2002.
New Brunswick Scientific,E. coliFermentation Using a BioFlo 100 Bench-Top Fermentor, (Edison NJ, USA) pp. 1-4, 2007.
J.M. Scientific, Economic fermentor and bioreactor, Laboratorytalk (online publication), Jul. 28, 2003.
Beck et al., Expression of human placental alkaline phosphatase inEscherichia coli, Protein Exp. Purif. 5(2):192-197, Apr. 1994, abstract only.
Ratledge et al., Effect of iron and zinc on growht patterns ofEscherichia coliin an iron-deficient medium, J. Bact. 87(4):823-827, Apr. 1964.
Darnell et al., Molecular Cell Biology, Scientific American Books:New York, 1986.
Wikipedia online encyclopedia, Lysogeny Broth, Jun. 9, 2009, accessed Jun. 2009.
Armitage et al., “Molecular and Biological Characterization of a Murine Ligand for CD40”Nature357(6373):80-82 (1992).
Aruffo et al., “CD44 is the Principal Cell Surface Receptor for Hyaluronate”Cell61:1303-1313 (Jun. 29, 1990).
Ashkenazi and Dixit., “Death Receptors: Signaling and Modulation.”Science. 281(5381):1305-1308 (1998).
Ashkenazi et al., “Protection Against Endotoxic Shock by a Tumor Necrosis Factor Receptor Immunoadhesin”Proc. Natl. Acad. Sci. 88:10535-10539 (Dec. 1991).
Banner et al., “Crystal Structure of the Soluble Human 55 kd TNF Receptor-Human TNFβ Complex: Implications for TNF Receptor Activation”Cell73:431-445 (1993).
Barr and Tomei, “Apoptosis and Its Role in Human Disease”Bio/Technology12:487-493 (1994).
Bodmer et al., “TRAMP, A Novel Apoptosis-Mediating Receptor with Sequence Homology to Tomor Necrosis Factor Receptor 1 and Fas(Apo-1/CD95).”Immunity. 6:79-88 (1997).
Brockhaus et al., “Identification of Two Types of Tumor Necrosis Factor Receptors on Human Cell Lines by Monoclonal Antibodies.”Proc. Natl. Acad. Sci. USA87:3127-3131 (1990).
Brojatsch et al., “CAR1, A TNFR-Related Protein, Is a Cellular Receptor for Cytopathic Avian Leukosis-Sarcoma Viruses and Mediates Apoptosis.”Cell. 87:845-855 (1996).
Browning et al., “Lymphotoxin β, a Novel Member of the TNF Family That Forms a Heteromeric Complex with Lymphotoxin on the Cell Surface”Cell72:847-856 (1993).
Cha et al., “2.8 A Resolution Crystal Structure of Human TRAIL, a Cytokine with Selective Antitumor Activity”Immunity11:253-261 (1999).
Cha et al., “Crystal Structure of TRAIL-DR5 Complex Identifies a Critical Role of the Unique Frame Insertion in Conferring Recognition Specificity”The Journal of Biological Chemistry, JBC Papers in Press vol. 275 (40) :31171-31177 (Jul. 11, 2000).
Cha et al., “Expression, purification and crystallization of-recombinant human TRAIL”Acta Chrystallographica, Section D: Biological Chrystallography55:1101-1104 (1999).
Chang et al., “High-Level Secretion of Human Growth Hormone byEscherichia coli” Gene55:189-196 (1987).
Chicheportiche et al., “TWEAK, A New Secreted Ligand in the tumor Necrosis Factor Family that Weakly Induces Apoptosis”Journal of Biological Chemistry272(51):32401-32410 (1997).
Chinnaiyan et al., “Signal Transduction by DR3, A Death Domain-Containing Receptor Related to TNFR-1 and CD95.”Science. 274:990-992 (1996).
Christianson, D., “Structural Biology of Zinc”Advances in Protein Chemistry42:281-355 (1991).
DeBoer et al., “Construction of a Tandem trp-lac Promoter and a Hybrid trp-lac Promoter for Efficient and Controlled Expression of the Human Growth Hormone Gene inEscherichia coli” Promoters: Structure and Function, New York: Praeger pp. 462-481 (1982).
Degli-Esposti et al., “Cloning and Characterization of TRAIL-R3, a Novel Member of the Emerging TRAIL Receptor Family”Journal of Experimental Medicine186(7):1165-1170 (1997).
Degli-Esposti et al., “The Novel Receptor TRAIL-R4 Induces Nf-κB and Protects against TRAIL-Mediated Apoptosis, yet Retains an Incomplete Death Domain”Immunity7 :813-820 (1997).
Feese et al, “Cation-promoted association of a regulatory and target protein is controlled by protein phosphorylation”Proc. Natl. Acad. 91:3544-3548 (1994).
Garcia et al., “TheE. colidnaY Gene Encodes an Arginine Transfer RNA.”Cell. 45:453-459 (1986).
Golstein, P., “Cell Death: TRAIL and its Receptors”Curr. Biol7:R750-R753 (1997).
Goodwin et al., “Molecular Cloning and Expression of the Type 1 and Type 2 Murine Receptors for Tumor Necrosis Factor.”Mol. Cell. Bio. 11:3020-3026 (1991).
Gruss and Dower, “Tumor Necrosis Factor Ligand Superfamily: Involvement in the Pathology of Malignant Lymphomas”Blood85:3378-3404 (1995).
Hale et al., “Demonstration of In Vitro and In Vivo Efficacy of Two Biologically Active Human Soluble TNF Receptors Expressed inE. coli.” J. Cell. Biochem. (abstract only, suppl. 15F; P 424) pp. 113 (1991).
Hohmann et al., “Two different cell types have different major receptors for human tumor necrosis factor (TNFα)”Journal of Biological Chemistry264 (25):14927-14934 (1989).
Hymowitz et al., “A unique zinc-binding site revealed by the high-resolution X-ray structure of homotrimeric Apo2L/TRAIL”Biochemistry39(4):633-640 (2000).
Hymowitz et al., “Triggering Cell Death: The Crystal Structure of Apo2L/TRAIL in a complex with Death Receptor 5”Molecular Cell4(4):563-571 (1999).
Itoh et al., “The Polypeptide Encoded by the cDNA for Human Cell Surface Antigen Fas Can Mediate Apoptosis.”Cell. 66:233-243 (1991).
Johnson et al., “Expression and Structure of the Human NGF Receptor”Cell47:545-554 (1986).
Karpusas et al., “The crystal structure of human interferon β at 2.2-A resolution”Proc. Natl. Acad. Sci. 94:11813-11818 (1997).
Kitson et al., “A Death-Domain-Containing Receptor that Mediates Apoptosis”Nature384:372-375 (1996).
Kohno et al., “A Second Tumor Necrosis Factor Receptor Gene Product Can Shed a Naturally Occurring Tumor Necrosis Factor Inhibitor.”Proc. Natl. Acad. Sci. USA87:8331-8335 (1990).
Komine et al., “Genomic Organization and Physical Mapping of the Transfer RNA Genes inEscherichia coliK12”J. Mol. Biol. 212:579-598 (1990).
Kunkel et al., “Rapid and Efficient Site-specific Mutagenesis Without Phenotypic Selection”Methods in Enzymology154:367-382 (1987).
Kunkel, T., “Rapid and Efficient Site-Specific Mutagenesis Without Phenotypic Selection

Affiliated with

Also associated with

Rating

Methods for making Apo-2 ligand using divalent metal ions does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods for making Apo-2 ligand using divalent metal ions, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for making Apo-2 ligand using divalent metal ions will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4199778